Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

The theory behind antibody drug conjugates (ADCs ... An increasing demand for ADC development and manufacturing capabilities With almost 90% of 2022 ADC revenues generated by substantial players ...

Lotte Biologics CEO James Park aims to secure ADC orders at U.S. plant this year Lotte Biologics new leadership seeks to ...

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan ...

New CEO James Park Delivers First Presentation at J.P. Morgan Healthcare Conference on 'Advancing as a Global CDMO Leader' ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

The market is projected to grow from $11B in 2024 to $40B by 2030, driven by both conventional bispecifics and advancements such as antibody-drug and radioligand conjugates. 2 Invenra has launched ...

In this interview, Technology Networks spoke with Dr. Sophie Mayle, Dr. Paul Royle and Dr. John Cardone from Bio-Rad's ...

SoluFlex Link overcomes the major challenge of instability in antibody-drug ... handle all stages of ADC drug development and production, from process development to manufacturing.